Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.J. Nieto.
Infections and atherosclerosis: new clues from an old hypothesis?.
Am J Epidemiol, 148 (1998), pp. 937-948
[2.]
Virus infections and atherosclerosis. Lancet. 1978;2:821-2.
[3.]
E.P. Benditt, J.M. Benditt.
Evidence for a monoclonal origin of human atherosclerotic plaques.
Proc Natl Acad Sci USA, 70 (1973), pp. 1753-1756
[4.]
C.G. Fabricant, J. Fabricant, C.R. Minick, M.M. Litrenta.
Virus-induced atherosclerosis in chickens.
J Exp Med, 148 (1978), pp. 335-340
[5.]
Y. Zhou, M. Shou, R. Harrell, E. Unger, T. Finkel, S. Epstein.
Effect of latent cytomegalovirus infection of rats on the neointimal response ot vascular ballon injury.
J Am Coll Cardiol, 29 (1997), pp. 420A
[6.]
J.B. Muhlestein, J.L. Anderson, E.H. Hammond, et al.
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.
Circulation, 97 (1998), pp. 633-636
[7.]
D.P. Hajjar, C.G. Fabricant, C.R. Minick, J. Fabricant.
Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation.
Am J Pathol, 122 (1986), pp. 62-70
[8.]
M.V. Kalayoglu, G.I. Byrne.
A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide.
Infect Immun, 66 (1998), pp. 5067-5072
[9.]
M.V. Kalayoglu, B. Hoerneman, D. LaVerda, S.G. Morrison, R.P. Morrison, G.I. Byrne.
Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae.
J Infect Dis, 180 (1999), pp. 780-790
[10.]
E. Speir, R. Modali, E.S. Huang, et al.
Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.
Science, 265 (1994), pp. 391-394
[11.]
J.L. Melnick, C. Hu, J. Burek, E. Adam, M.E. DeBakey.
Cytomegalovirus DNA in arterial walls of patients with atherosclerosis.
J Med Virol, 42 (1994), pp. 170-174
[12.]
L.A. Campbell, E.R. O'Brien, A.L. Cappuccio, et al.
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues.
J Infect Dis, 172 (1995), pp. 585-588
[13.]
E. Adam, J.L. Melnick, J.L. Probtsfield, et al.
High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis.
Lancet, 2 (1987), pp. 291-293
[14.]
P. Saikku, M. Leinonen, K. Mattila, et al.
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Lancet, 2 (1988), pp. 983-986
[15.]
M.A. Mendall, P.M. Goggin, N. Molineaux, et al.
Relation of Helicobacter pylori infection and coronary heart disease.
Br Heart J, 71 (1994), pp. 437-439
[16.]
J. Danesh, R. Collins, R. Peto.
Chronic infections and coronary heart disease: is there a link?.
Lancet, 350 (1997), pp. 430-436
[17.]
P.M. Ridker, R.B. Kundsin, M.J. Stampfer, S. Poulin, C.H. Hennekens.
Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction.
Circulation, 99 (1999), pp. 1161-1164
[18.]
F.J. Nieto, A.R. Folsom, P.D. Sorlie, J.T. Grayston, S.P. Wang, L.E. Chambless.
Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study.
Am J Epidemiol, 150 (1999), pp. 149-156
[19.]
D.P. Strachan, D. Carrington, M.A. Mendall, et al.
Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study.
BMJ, 318 (1999), pp. 1035-1039
[20.]
B. Fagerberg, J. Gnarpe, H. Gnarpe, S. Agewall, J. Wikstrand.
Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension.
Stroke, 30 (1999), pp. 299-305
[21.]
P.M. Ridker, C.H. Hennekens, M.J. Stampfer, F. Wang.
Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke.
Circulation, 98 (1998), pp. 2796-2799
[22.]
Sorlie PP, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpesvirus I and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2000; en prensa.
[23.]
A.R. Folsom, F.J. Nieto, P. Sorlie, L.E. Chambless, D.Y. Graham.
Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators.
Circulation, 98 (1998), pp. 845-850
[24.]
P. Whincup, J. Danesh, M. Walker.
y cols. Prospective Study of Potentially Virulent Strains of Helicobacter pylori and Coronary Heart Disease in Middle-Aged Men.
Circulation, 101 (2000), pp. 1647-1652
[25.]
E. Gurfinkel, G. Bozovich, A. Daroca, E. Beck, B. Mautner.
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group.
Lancet, 350 (1997), pp. 404-407
[26.]
S. Gupta, E.W. Leatham, D. Carrington, M.A. Mendall, J.C. Kaski, A.J. Camm.
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
Circulation, 96 (1997), pp. 404-407
[27.]
E. Gurfinkel, G. Bozovich, E. Beck, E. Testa, B. Livellara, B. Mautner.
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study.
Eur Heart J, 20 (1999), pp. 121-127
[28.]
J.L. Anderson, J.B. Muhlestein, J. Carlquist.
y cols. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
Circulation, 99 (1999), pp. 1540-1547
[29.]
J.T. Grayston.
Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events.
Circulation, 97 (1998), pp. 1669-1670
[30.]
F.J. Nieto.
Viruses and atherosclerosis: A critical review of the epidemiologic evidence.
Am Heart J, 138 (1999), pp. 453-460
[31.]
C.A. Bruggeman.
Cytomegalovirus and latency: an overview.
Virchows Arch B Cell Pathol Incl Mol Pathol, 64 (1993), pp. 325-333
[32.]
R. Ross.
Atherosclerosis: an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[33.]
M. Roivanen, G. Alfthan, P. Joousilahti.
Enterovirus infections as a possible risk factor for myocardial infarction.
Circulation, 98 (1999), pp. 2534-2537
[34.]
J. Zhu, A. Quyyumi, J. Norman.
Total pathogen burden contributes incrementally to coronary artery disease risk and to C-reactive protein levels.
Circulation, 98 (1998), pp. 1-42
[35.]
J. Beck, R. Garcia, G. Heiss, P.S. Vokonas, S. Offenbacher.
Periodontal disease and cardiovascular disease.
J Periodontol, 67 (1996), pp. 1123-1137
[36.]
K.J. Mattila.
Viral and bacterial infections in patients with acute myocardial infarction.
J Intern Med, 225 (1989), pp. 293-296
[37.]
P.Y. Lovey, A. Morabia, D. Bleed, O. Peter, G. Dupuis, J. Petite.
Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study.
BMJ, 319 (1999), pp. 284-286
[38.]
J. Danesh, R. Newton, V. Beral.
Epidemiology: A human Germ project?.
Nature, 389 (1997), pp. 21-24
[39.]
F.J. Nieto, M. Szklo, P.D. Sorlie.
Cytomegalovirus infection and coronary heart disease.
Circulation, 100 (1999), pp. 139
[40.]
J.P. Strong, H.C. McGill.
Jr. The pediatric aspects of atherosclerosis.
J Atheroscler Res, 9 (1969), pp. 251-265
[41.]
J.P. Strong, G.T. Malcom, C.A. McMahan.
y cols. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study.
JAMA, 281 (1999), pp. 727-735
[42.]
A.R. Folsom.
Antibiotics for prevention of myocardial infarction?.
Not yet! JAMA, 281 (1999), pp. 461-462
[43.]
R.C. Brunham, D. Zhang.
Transgene as vaccine for chlamydia.
Am Heart J, 138 (1999), pp. S519-S522
Copyright © 2000. Sociedad Española de Salud Pública y Administración Sanitaria
